Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06788639 | A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06088888 | TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia | recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 |
| Feb 21, 2025 |
| clinicaltrials |
| NCT06453902 | TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients | recruiting | Phase 2 | 40 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06827899 | Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML | recruiting | Phase 2 | 66 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05603884 | VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 2 | 66 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05870995 | Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia | recruiting | Phase 2 | 100 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT05881265 | Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia | recruiting | Phase 2 | 30 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT05991908 | Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies | recruiting | Phase 3 | 222 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06557161 | A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL | recruiting | Phase 2 | 170 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06559345 | A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL | recruiting | Phase 2 | 276 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06564493 | A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL | recruiting | Phase 2 | 170 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06564545 | A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL | recruiting | Phase 2 | 276 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06361329 | Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL | recruiting | Phase 3 | 81 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06821880 | Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project(PRO-SID) | recruiting | — | 120 | Medical University InnsbruckOTHER | 2 | Feb 12, 2025 | clinicaltrials |
| NCT06814444 | Study of the Immunological Infiltrate and Immunometabolic Immunometabolic Profile of Patients with Acute Leukaemia | recruiting | — | 170 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04929899 | Bright Ideas - CIN Feasibility Study | recruiting | N/A | 75 | The Hospital for Sick ChildrenOTHER | 2 | Jan 31, 2025 | clinicaltrials |
| NCT06794762 | Effects of Core Stabilization Exercises in Children with Acute Lymphoblastic Leukemia | recruiting | N/A | 34 | Karamanoğlu Mehmetbey UniversityOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06802718 | Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia | recruiting | Phase 3 | 96 | Peking University People's HospitalOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06764459 | Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments(CLEV-LAM-2022) | recruiting | — | 20 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06626672 | Digital Health Promotion for Children With Congenital Heart Disease and Their Guardians | recruiting | N/A | 60 | Deutsches Herzzentrum MuenchenOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06793241 | Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia | recruiting | Early Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05601726 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients(ODYSSEY) | recruiting | Phase 1 / Phase 2 | 36 | Advanced BioDesignINDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06096272 | Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy | recruiting | N/A | 30 | Children's Hospital Los AngelesOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06783790 | Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06783816 | A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors | recruiting | N/A | 45 | Shanxi Bethune HospitalOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06785077 | Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors | recruiting | N/A | 157 | European Institute of OncologyOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06781515 | Assessment of Disease Burden in Hairy Cell Leukemia(BRAF) | recruiting | N/A | 45 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT05488548 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 75 | Epigenetix, Inc.INDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06774677 | Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT05281809 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 30 | John ListerOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06179524 | CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL | recruiting | Phase 2 | 100 | Beijing Yongtai Ruike Biotechnology Company LtdINDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05528939 | Feasibility/Acceptability of Attentional-Control Training in Survivors(FAACTS) | recruiting | N/A | 50 | Children's National Research InstituteOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06764524 | Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06760260 | Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 7 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06762132 | A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06756152 | Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis | recruiting | Phase 2 / Phase 3 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06752785 | CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. | recruiting | Phase 1 | 10 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06741722 | Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML | recruiting | Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746519 | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 135 | Chen SuningOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05477589 | Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML(SCRIPT-AML) | recruiting | Phase 3 | 170 | Vastra Gotaland RegionOTHER_GOV | 10 | Dec 19, 2024 | clinicaltrials |
| NCT04466059 | Better Leukemia Diagnostics Through AI (BELUGA)(BELUGA) | recruiting | — | 25,000 | Munich Leukemia LaboratoryINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05046444 | Solving Riddles Through Sequencing(SIRIUS) | recruiting | — | 100 | Munich Leukemia LaboratoryINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06731699 | A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS | recruiting | Phase 1 | 72 | Chengdu FenDi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05682924 | Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib | recruiting | — | 105 | Samara State Medical UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06101381 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma(CARTHEDRALL) | recruiting | Phase 1 / Phase 2 | 81 | University of Sao PauloOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06722638 | Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia(VIRALL) | recruiting | N/A | 40 | Children's National Research InstituteOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06724536 | Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML(MICROBIO-LMC) | recruiting | — | 100 | Carmen FavaOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | recruiting | Phase 1 | 54 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Dec 6, 2024 | clinicaltrials |
| NCT06702566 | The Effect of Serum Ferritin in irAE | recruiting | N/A | 1,500 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06696833 | Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia | recruiting | Early Phase 1 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 20, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 24, 2025source: clinicaltrials